Kura Oncology, Inc.’s Post

Coming out of #ASCO24, we’re excited to further our work in supporting patients living with difficult-to-treat cancers such as gastroesophageal adenocarcinoma (GEA). HER2 has emerged as a compelling target for patients whose cancer displays HER2-positivity, including some GEA patients, which is why testing for HER2-expression in patients diagnosed with GEA is critical to determining the appropriate treatment option. Hear from Elaina Gartner, Vice President Medical, Late-Stage Development, Oncology Clinical Development, as she details more about the role of #HER2 in GEA. https://bit.ly/3Rier2V

Patients and society won’t reap the benefits of precision oncology unless we democratize this data, that is, make it available to the patients who need it when they need it. With a few practical improvements to current care pathways, we could achieve this, meet the need for urgency, and empower patients. Stacy Hurt 🌻, Parexel's Chief Patient Officer and a stage 4 cancer survivor, highlights three things we MUST do to ensure all patients can potentially benefit from precision oncology in our New Medicines, Novel Insights report: https://lnkd.in/gBkJMKt2 #PrecisionOncology #NovelInsights #PatientsFirst #PatientData #ASCO24

Looking forward to the research that will be shared at ASCO GU later this week, including the culmination of a project I had the honor of working on with Mihaela Georgiana Musat, Hoora Moradian, PhD, Ioana Gulas, Mairead Kearney, Silke Guenther, Srikala S. Sridhar, and Richard O'Dwyer: Clinical outcomes with split-dose cisplatin-based regimens in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a systematic literature review (SLR) and network meta-analysis (NMA).

Cancer patients often have to choose between an academic center, hospital, community oncology practice or a combination when it comes to receiving care. Large academic centers or hospitals tend to draw patients due to their size and variety of services. In a new case study out today, FCS takes a deeper look into community oncology practices and reveals some unknown and appealing benefits. Several factors, such as cost, location and personalized care, impact and improve patient care based on where the care is received. Learn why the site of service matters in oncology care: https://lnkd.in/eA3MYQgs

We highlight the overuse of terms such as 'tolerable', 'manageable' and 'acceptable' in reports of clinical trials - Edward Cliff oncodaily.com/20876.html #oncodaily #oncology #cancer #JAMA #research

Your Trials Need Personalized Care! When you work with Stiris, you get: •Expertise in oncology clinical trials that you can tap into to maximize the likelihood of success with your trials. •Team stability that keeps your sites happy, and allows you to keep the study momentum going. •Access to Clinical Science expertise that comes from 25 years of oncology experience at a top-five pharma company. Reach out ([email protected]) to hear other ways we can provide value to you, or to meet with our President & CEO Shantal Feltham, and head of Clinical Science Carrie Hamilton at the 13th Clinical Trials in Oncology East Coast Conference. #Oncology #Cancer #ClinicalResearch #ClinicalTrials #StirisResearch

Staying on or ahead of schedule within a clinical trial helps patients gain access to therapy quicker and reduce the resources required for drug development. Learn how UBC has been able to achieve speed and quality in a rescued Phase III study here: https://hubs.li/Q026VzNC0 #PatientsFirst #Oncology #ProstateCancer #PhaseIII #ClinicalTrials #Decentralized

📢📰 Published in The Journal of Clinical Oncology, this study concluded that Liso-cel demonstrate ⬆️CR rate & deep, durable responses with⬇️incidence of grade ≥3 CRS, NE, & infections in pts with heavily pretreated R/R MCL, including those with⬆️risk, aggressive disease READ➡️https://lnkd.in/eN5pKmqh

"Diverse populations, accelerating oncology innovation." N-Power Medicine, Inc. is dedicated to transforming community oncology practices into high-performing clinical trial centers, focusing on improving patient enrollment and diversity in clinical research. Learn more at https://lnkd.in/gaY9uEkb #Oncology #ClinicalTrials #SoHCSpotlights

🚀 Exciting news! ConcertAI has acquired CancerLinQ®, enhancing oncology research and patient care. "We're committing over $250m to achieve the highest quality care," says CEO Jeff Elton. This partnership aims to broaden CancerLinQ's data utilization, leveraging real-world insights, analytics, and AI for accelerated clinical research and improved cancer care. ASCO CEO Clifford Hudis adds, "CancerLinQ will amplify its impact while supporting quality improvement initiatives." Empowering oncology practices and patients alike! https://lnkd.in/dBrJz2ru 📰 Follow Practical Patient Care to receive the latest healthcare news daily that is important to you and to subscribe to our weekly newsletter #PracticalPatientCare #ConcertAI #CancerLinQ #OncologyInnovation #HealthcareTech